People with AIDS also have HIV, as HIV is the first stage of AIDS. Learn about the differences, how the conditions overlap, ...

A research group led by Professor Wei Li from the Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Toho ...

The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...

The global HIV antivirals market is experiencing substantial growth, fueled by rising global awareness, advancements in pharmaceutical research, and the increasing adoption of innovative treatment ...

In January, the White House ordered an immediate halt to the distribution of HIV medications by U.S.-funded foreign clinics, ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries.

The global HIV drugs industry was valued at USD 28.6 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to ...

India's largest drugmaker Sun Pharmaceutical Industries Ltd and its peers Cipla Ltd., Glenmark ... and psychotropic drugs, as well as anti-retroviral drugs (including HIV-treating medicines).

How does Cipla navigate the seismic shifts in global pharma, from regulatory pressures in the US to the rise of AI-driven drug discovery? What does the future of pharmaceutical innovation hold, and ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.

How does Cipla navigate the seismic shifts in global pharma, from regulatory pressures in the US to the rise of AI-driven drug discovery? What does the future of pharmaceutical innovation hold ...